295 related articles for article (PubMed ID: 27123911)
1. Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy.
Raju A; Shetty S; Cai B; D'Souza AO
J Manag Care Spec Pharm; 2016 May; 22(5):483-92. PubMed ID: 27123911
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
[TBL] [Abstract][Full Text] [Related]
3. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data model: A retrospective observational study.
Lee KA; Jin HY; Kim YJ; Kim SS; Cho EH; Park TS
Medicine (Baltimore); 2022 Feb; 101(8):e28823. PubMed ID: 35212277
[TBL] [Abstract][Full Text] [Related]
4. Association Between Weight Change, Clinical Outcomes, and Health Care Costs in Patients with Type 2 Diabetes.
Mukherjee J; Sternhufvud C; Smith N; Bell K; Stott-Miller M; McMorrow D; Johnston S
J Manag Care Spec Pharm; 2016 May; 22(5):449-66. PubMed ID: 27123909
[TBL] [Abstract][Full Text] [Related]
5. Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Rascati KL; Worley K; Meah Y; Everhart D
J Manag Care Spec Pharm; 2017 Mar; 23(3):299-306. PubMed ID: 28230454
[TBL] [Abstract][Full Text] [Related]
6. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
7. Progression to treatment failure among Chinese patients with type 2 diabetes initiated on metformin versus sulphonylurea monotherapy--The Hong Kong Diabetes Registry.
Jiang G; Luk AO; Yang X; Wang Y; Tam CHT; Lau SH; Ozaki R; Kong APS; Tong PC; Chow CC; Chan JCN; So WY; Ma RCW
Diabetes Res Clin Pract; 2016 Feb; 112():57-64. PubMed ID: 26703273
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
Del Prato S; Taskinen MR; Owens DR; von Eynatten M; Emser A; Gong Y; Chiavetta S; Patel S; Woerle HJ
J Diabetes Complications; 2013; 27(3):274-9. PubMed ID: 23403068
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
Guo XH; Feng ZK; Xu LH
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
[No Abstract] [Full Text] [Related]
11. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Gallwitz B; Rosenstock J; Rauch T; Bhattacharya S; Patel S; von Eynatten M; Dugi KA; Woerle HJ
Lancet; 2012 Aug; 380(9840):475-83. PubMed ID: 22748821
[TBL] [Abstract][Full Text] [Related]
12. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylurea monotherapy and emergency room utilization among elderly patients with type 2 diabetes.
Rajpathak SN; Fu C; Brodovicz K; Engel SS; Heaton PC
Diabetes Res Clin Pract; 2015 Sep; 109(3):507-12. PubMed ID: 26123984
[TBL] [Abstract][Full Text] [Related]
14. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas.
Alemayehu B; Liu J; Rajpathak S; Engel SS
J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
[TBL] [Abstract][Full Text] [Related]
16. Risk of hypoglycaemia in people aged ≥65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus.
Nauck M; Araki A; Hehnke U; Plat A; Clark D; Khunti K
Int J Clin Pract; 2018 Oct; 72(10):e13240. PubMed ID: 30216648
[TBL] [Abstract][Full Text] [Related]
17. Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease.
Mehta S; Ghosh S; Sander S; Kuti E; Mountford WK
J Manag Care Spec Pharm; 2018 Mar; 24(3):280-290. PubMed ID: 29485954
[TBL] [Abstract][Full Text] [Related]
18. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
Mamza J; Mehta R; Donnelly R; Idris I
Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
[TBL] [Abstract][Full Text] [Related]
19. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study.
Alvarez Guisasola F; Mavros P; Nocea G; Alemao E; Alexander CM; Yin D
Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():8-15. PubMed ID: 18435669
[TBL] [Abstract][Full Text] [Related]
20. Actionable Real-World Evidence to Improve Health Outcomes and Reduce Medical Spending Among Risk-Stratified Patients with Diabetes.
Garry EM; Schneeweiss S; Eapen S; Petruski-Ivleva N; Cheever E; Murk W; Rajan A; Rassen JA; Gambino D; Jang H; Rubin E; Jan S
J Manag Care Spec Pharm; 2019 Dec; 25(12):1442-1452. PubMed ID: 31778623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
